Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;4(2):106-116.
doi: 10.1007/s40471-017-0104-1. Epub 2017 Apr 18.

Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy

Susan E Andrade  1 , Anick Bérard  2 , Hedvig M E Nordeng  3   4 , Mollie E Wood  3 , Marleen M H J van Gelder  5   6 , Sengwee Toh  7
Affiliations
Review

Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy

Susan E Andrade et al. Curr Epidemiol Rep. 2017.

Erratum in

Abstract

Purpose of review: Administrative claims databases, which collect reimbursement-related information generated from healthcare encounters, are increasingly used to evaluate medication safety in pregnancy. We reviewed the strengths and limitations of claims-only databases and how other data sources may be used to improve the accuracy and completeness of information critical for studying medication safety in pregnancy.

Recent findings: Research on medication safety in pregnancy requires information on pregnancy episodes, mother-infant linkage, medication exposure, gestational age, maternal and birth outcomes, confounding factors, and (in some studies) long-term follow-up data. Claims data reliably identifies live births and possibly other pregnancies. It allows mother-infant linkage and has prospectively collected prescription medication information. Its diagnosis and procedure information allows estimation of gestational age. It captures maternal medical conditions but generally has incomplete data on reproductive and lifestyle factors. It has information on certain, typically short-term maternal and infant outcomes that may require chart review confirmation. Other data sources including electronic health records and birth registries can augment claims data or be analyzed alone. Interviews, surveys, or biological samples provide additional information. Nationwide and regional birth and pregnancy registries, such as those in several European and North American countries, generally contain more complete information essential for pregnancy research compared to claims-only databases.

Summary: Claims data offers several advantages in medication safety in pregnancy research. Its limitations can be partially addressed by linking it with other data sources or supplementing with primary data collection. Rigorous assessment of data quality and completeness is recommended regardless of data sources.

Keywords: Administrative claims data; Birth registry; Electronic health records; Pharmacoepidemiology; Pregnancy.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsAnick Bérard, Hedvig M.E. Nordeng, Mollie E. Wood, Marleen M.H.J. van Gelder, and Sengwee Toh each declare no potential conflict of interest. Susan E. Andrade reports a grant from Pfizer, Inc., outside the submitted work.This article does not contain any studies with human or animal subjects performed by any of the authors.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Naleway AL, Gold R, Kurosky S, Riedlinger K, Henninger ML, Nordin JD, et al. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine. 2013;31(27):2898–2903. doi: 10.1016/j.vaccine.2013.03.069. - DOI - PubMed
    1. Margulis AV, Palmsten K, Andrade SE, Charlton RA, Hardy JR, Cooper WO, et al. Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results. Pharmacoepidemiol Drug Saf. 2015;24(4):335–342. doi: 10.1002/pds.3743. - DOI - PubMed
    1. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf. 2005;14(12):829–836. doi: 10.1002/pds.1100. - DOI - PubMed
    1. Berard A, Sheehy O. The Quebec Pregnancy Cohort—prevalence of medication use during gestation and pregnancy outcomes. PLoS One. 2014;9(4):e93870. doi: 10.1371/journal.pone.0093870. - DOI - PMC - PubMed
    1. Palmsten K, Huybrechts KF, Mogun H, Kowal MK, Williams PL, Michels KB, et al. Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations. PLoS One. 2013;8(6):e67405. doi: 10.1371/journal.pone.0067405. - DOI - PMC - PubMed

LinkOut - more resources